Bioprocessing & cGMP

In this Issue:

Whether companies have own resources for biologics production or whether contract research organisations do the job: novel molecule formats, cell & gene therapies, more productive cell lines and continous manufacturing challenge their capabilities to innovate and differentiate from the rest of the pack.

• GMP and new processes: Be prepared for hassle
• Interview: Expanding into the commercial space, Franzpeter Bracht, COO, Celonics AG
• Statement: “Learning from the small molecule supply chain”, Rutger Oudejans, Brand Director, UBM
• Biomanufacturing news

You want to be part of European Biotechnology? Get on Board!

Marketing Contacts 

Andreas Macht
Tel: +49-30-264921-54
a.macht(at)biocom.de

Oliver Schnell
Tel: +49-30-264921-45
o.schnell(at)biocom.de

Editorial Contact

Thomas Gabrielczyk
Tel: +49-30-264921-50
t.gabrielczyk(at)biocom.de